A detailed history of Royal Bank Of Canada transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Royal Bank Of Canada holds 1,727 shares of ASND stock, worth $224,181. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,727
Previous 7,445 76.8%
Holding current value
$224,181
Previous $1.02 Million 74.68%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$113.0 - $153.43 $646,134 - $877,312
-5,718 Reduced 76.8%
1,727 $257,000
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $36,078 - $45,793
298 Added 4.17%
7,445 $1.02 Million
Q1 2024

Nov 05, 2024

SELL
$123.45 - $159.4 $36,788 - $47,501
-298 Reduced 4.0%
7,147 $1.08 Million
Q1 2024

May 15, 2024

SELL
$123.45 - $159.4 $35,553 - $45,907
-288 Reduced 3.87%
7,147 $1.08 Million
Q4 2023

Feb 14, 2024

BUY
$86.1 - $127.36 $49,249 - $72,849
572 Added 8.33%
7,435 $936,000
Q3 2023

Nov 14, 2023

SELL
$86.5 - $103.97 $272,475 - $327,505
-3,150 Reduced 31.46%
6,863 $642,000
Q2 2023

Aug 14, 2023

BUY
$69.96 - $97.84 $630,549 - $881,831
9,013 Added 901.3%
10,013 $893,000
Q1 2023

May 15, 2023

SELL
$104.9 - $126.78 $6,923 - $8,367
-66 Reduced 6.19%
1,000 $107,000
Q4 2022

Feb 14, 2023

SELL
$99.42 - $131.97 $43,446 - $57,670
-437 Reduced 29.08%
1,066 $130,000
Q3 2022

Nov 14, 2022

SELL
$84.03 - $110.23 $81,593 - $107,033
-971 Reduced 39.25%
1,503 $155,000
Q2 2022

Aug 15, 2022

BUY
$78.08 - $117.61 $6,636 - $9,996
85 Added 3.56%
2,474 $230,000
Q1 2022

May 16, 2022

BUY
$102.18 - $135.75 $74,795 - $99,369
732 Added 44.18%
2,389 $281,000
Q4 2021

Feb 14, 2022

SELL
$127.1 - $169.66 $64,693 - $86,356
-509 Reduced 23.5%
1,657 $223,000
Q3 2021

Nov 15, 2021

BUY
$112.67 - $176.92 $34,927 - $54,845
310 Added 16.7%
2,166 $345,000
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $225,726 - $269,658
1,856 New
1,856 $244,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.24B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.